Investor Presentaiton

FY16 Guidance Consolidated Revenues • To remain flat or show a decline over FY15. Consolidated Profits • In addition to the above revenue impact, profits may be adversely impacted due to certain expenses/charges arising out of integration as well as cGMP remedial actions. Ranbaxy integration Synergy Investing for Future © Sun Pharmaceutical Industries Limited. All Rights Reserved. • To incur certain integration charges in order to generate long- term synergies • Target US$ 300 million in synergy benefits from the Ranbaxy acquisition by FY18 • Invest in R&D and in building critical talent for enhancing our ophthalmic and OTC teams in US as well as for forming a dedicated team for MK-3222 SUN PHARMA 54

View entire presentation